Item 8.01 Other Events.
On June 7, 2021, C4 Therapeutics, Inc. (the "Company") issued a press release
entitled "C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective
Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation."
The Company also posted a corporate presentation on CFT8919 pre-clinical data
for its investor call on its website at
https://ir.c4therapeutics.com/events-presentations. A copy of the press release
and the corporate presentation are filed as Exhibits 99.1 and 99.2,
respectively, to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending
on the relevant item requiring such exhibit, in accordance with the provisions
of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.
Exhibit
Number Description
99.1 Press Release dated June 7, 2021
99.2 Corporate Presentation of the Company dated June 7, 2021
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses